西普尼公告，根据对集团截至2025年11月30日止11个月之未经审核综合管理帐目之初步审阅，其录得净 利润超过人民币9000万元。根据集团之现有资料，相对于截至2024年12月31日止年度净利润约人民币 4900万元，预期集团截至2025年12月31日止年度将录得更高的净利润。集团净利润的预期增长主要基 于：(1)由于饰品的销售收入增加；及(2)由于销售手表的毛利率增加。 2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中西普尼(02583)获 纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效，届 时沪深交易所会相应调整港股通可投资标的范围。据中金研报，西普尼有可能被调入港股通，因其满足 了包括市值、流动性和上市时间等在内的一系列标准。 ...

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Xirui (02507) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to CICC's research report, Xirui is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Western Securities (002673) noted that Xirui launched the VisionJet G3 product on February 3, with continuous price increases and upgrades in intelligence and comfort [1] - The firm believes that with the gradual acquisition of new orders for better-structured products like VisionJet G3 and SRG7+, the overall product structure will improve year-on-year, enhancing profitability [1]

2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中OSL集团(00863) 获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效， 届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，OSL集团有可能被调入港股通，因其 满足了包括市值、流动性和上市时间等在内的一系列标准。 OSL集团此前公告，本集团预期于2025财年(截至2025年12月31日止年度)取得持续经营业务的净亏损介 乎约3.7亿港元至4.3亿港元，而截至2024年12月31日止年度(2024财年)则取得持续经营业务的溢利约 5500万港元，原因是本集团作出重要投资以奠定未来增长的稳健基础。 ...

Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, including the inclusion of LeShuShi (02698) in the Hang Seng Composite Index, effective March 9, 2026 [1] Company Overview - LeShuShi is a multinational hygiene products company focused on rapidly developing emerging markets in Africa, Latin America, and Central Asia, primarily engaged in the development, manufacturing, and sales of baby diapers, baby pull-ups, sanitary napkins, and wet wipes [1] - The company operates under several brands, including Softcare, Veesper, Maya, Cuettie, and Clincleer, with product sales covering over 30 countries in West Africa, East Africa, and Central Africa [1] - A significant portion of the company's revenue during the historical period came from sales to African customers [1] Market Implications - The inclusion of LeShuShi in the Hang Seng Composite Index may lead to its potential addition to the Hong Kong Stock Connect, as it meets various criteria such as market capitalization, liquidity, and listing duration [1]

截至该公告日期，该款疫苗成为中国首款且唯一一款获批上市的全人群全剂量三价流感病毒亚单位疫 苗。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风 险低等优势。 2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中中慧生物- B(02627)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一) 起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，中慧生物-B有可能被调入港 股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 中慧生物-B(02627)发布公告，中国国家药品监督管理局已批准本集团针对所有年龄组别的三价流感病 毒亚单位疫苗的新药申请。 ...

2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中维立志博- B(09887)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一) 起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，维立志博-B有可能被调入港 股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 维立志博-B公告，评价维利信 (PD-L1/4-1BB双特异性抗体奥帕替苏米单抗， LBL-024)用于治疗复发性 或转移性三阴性乳腺癌的Ib/II期临床研究首例患者已成功用药。本次开展的开放标签、多中心Ib/II期临 床研究由江苏省人民医院殷咏梅教授牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单 抗单独给药或联合白蛋白结合型紫杉醇治疗复发性或转移性三阴性乳腺癌患者的疗效及安全性。 ...

交银国际近期发布研报称，首次覆盖劲方医药，给予买入评级，目标价51港元。交银国际表示，作为一 家扎根中国内地、拥有全球视野的创新药企，劲方医药组建了一支平均拥有逾20年行业经验、执行力较 强的核心管理团队，建立了一条包括6款临床阶段候选药物的药物管线。 2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中劲方医药- B(02595)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一) 起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，劲方医药有可能被调入港股 通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

Core Viewpoint - The Hang Seng Index Company announced the inclusion of Xipuni (02583) in the Hang Seng Composite Index, effective March 9, 2026, following a quarterly review, which may also lead to its inclusion in the Stock Connect program due to meeting various criteria [1] Group 1: Company Performance - Xipuni reported a preliminary net profit exceeding RMB 90 million for the 11 months ending November 30, 2025, indicating a significant increase compared to a net profit of approximately RMB 49 million for the year ending December 31, 2024 [1] - The expected growth in net profit for Xipuni is attributed to an increase in sales revenue from jewelry and an improvement in the gross margin from watch sales [1]

Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with Jiaxin International Resources (03858) being included in the Hang Seng Composite Index, effective from March 9, 2026 [1] Group 1: Company Performance - Jiaxin International Resources is expected to turn a loss into a profit, projecting a net profit attributable to shareholders of approximately HKD 300 million to HKD 340 million for the year ending December 31, 2025, compared to a net loss of HKD 173 million for the year ending December 31, 2024 [1] - The anticipated turnaround is primarily due to the group not generating any revenue in 2024 as it had not commenced operations, leading to the reported loss [1] Group 2: Market Impact - The inclusion of Jiaxin International Resources in the Hang Seng Composite Index may lead to its potential addition to the Stock Connect program, as it meets various criteria including market capitalization, liquidity, and listing duration [1] - The adjustments to the eligible stocks for the Hong Kong Stock Connect will be made accordingly by the Shanghai and Shenzhen stock exchanges [1]

Core Viewpoint - The Hang Seng Index Company announced the results of the quarterly review for the Hang Seng Index series, with Innovation Industry (02788) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Group 1: Company Information - Innovation Industry was officially listed on the Hong Kong Stock Exchange on November 24, 2025, with an issue price of HKD 10.99 per share, raising approximately HKD 5.5 billion [1] - The company attracted 17 well-known cornerstone investors, including Hillhouse, China Hongqiao, Taikang Life, Jinglin, Orix, China Pacific Insurance, GF Fund, and Winton Fund, with a total subscription amount of approximately USD 351 million, indicating strong institutional investor confidence in its fundamentals [1] Group 2: Market Impact - The inclusion of Innovation Industry in the Hang Seng Composite Index may lead to its potential addition to the Hong Kong Stock Connect, as it meets various criteria including market capitalization, liquidity, and listing duration [1] - The adjustment in the eligible stocks for the Hong Kong Stock Connect will be made accordingly by the Shanghai and Shenzhen Stock Exchanges [1]